Unaudited Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2018		Dec. 31, 2017
Current Assets
Cash and cash equivalents (variable interest entity restricted - 2018: $18; 2017: $19)	$ 490		$ 576
Trade receivables - third party and affiliates (net of allowance for doubtful accounts - 2018: $9; 2017: $9; variable interest entity restricted - 2018: $5; 2017: $5)	1,205		986
Non-trade receivables, net (variable interest entity restricted - 2018: $1; 2017: $0)	271		244
Inventories	955		900
Marketable securities, at fair value	32		32
Other assets	53		54
Total current assets	3,006		2,792
Investments in affiliates	979		976
Property, plant and equipment (net of accumulated depreciation - 2018: $2,686; 2017: $2,584; variable interest entity restricted - 2018: $689; 2017: $697)	3,801		3,762
Deferred income taxes	182		366
Other assets (variable interest entity restricted - 2018: $7; 2017: $6)	369		338
Goodwill	1,107	[1]	1,003
Intangible assets (variable interest entity restricted - 2018: $25; 2017: $25)	336		301
Total assets	9,780		9,538
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	425		326
Trade payables - third party and affiliates	797		807
Other liabilities	266		354
Income taxes payable	114		72
Total current liabilities	1,602		1,559
Long-term debt, net of unamortized deferred financing costs	3,343		3,315
Deferred income taxes	219		211
Uncertain tax positions	152		156
Benefit obligations	582		585
Other liabilities	217		413
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2018 and 2017: 0 issued and outstanding)	0		0
Treasury stock, at cost (2018: 32,387,713 shares; 2017: 32,387,713 shares)	(2,031)		(2,031)
Additional paid-in capital	192		175
Retained earnings	5,220		4,920
Accumulated other comprehensive income (loss), net	(128)		(177)
Total Celanese Corporation stockholders' equity	3,253		2,887
Noncontrolling interests	412		412
Total equity	3,665		3,299
Total liabilities and equity	9,780		9,538
Series A common stock, $0.0001 par value, 400,000,000 shares authorized (2018: 168,243,423 issued and 135,855,710 outstanding; 2017: 168,156,969 issued and 135,769,256 outstanding)
Stockholders' Equity
Common stock	0		0
Series B common stock, $0.0001 par value, 100,000,000 shares authorized (2018 and 2017: 0 issued and outstanding)
Stockholders' Equity
Common stock	$ 0		$ 0

[1] There were $0 million of accumulated impairment losses as of March 31, 2018.